Cancer Research 20 February 2026 - 9 March 2026

Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3
···

Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3

Relmada Therapeutics will raise about $160 million in a private placement, priced at $4.75 a share, after reporting 12-month data showing a 76% complete response rate for NDV-01 in non-muscle invasive bladder cancer. The financing, expected to close by March 11, follows FDA feedback backing late-stage studies. NDV-01 showed no cases of disease progression or severe side effects among 25 patients at 12 months.
March 9, 2026
Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test
···

Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test

Grail shares plunged 49.5% to $51.26 by midday Friday after its NHS-Galleri trial missed the primary endpoint of reducing stage III-IV cancers. The company said it would extend follow-up and submit results to ASCO. Over 10 million shares traded. Galleri’s FDA approval process continues, but analysts flagged uncertainty over insurance coverage.
February 20, 2026